Reduction of graft-versus-host reactivity after small bowel transplantation: ex vivo treatment of intestinal allografts with an anti-T cell immunotoxin.
A specific T lymphocyte immunotoxin was used to pre-treat small bowel grafts in an attempt to prevent graft-versus-host (GVH) reactivity and GVH disease in a rat transplant model. The immunotoxin used was a conjugate of the anti-CD5 MoAb MRC OX-19 with ricin A chain. The grafts were perfused ex vivo with a standard solution of immunotoxin followed by incubation at 4 degrees C for 1 h before transplantation. In a semi-allogeneic strain combination (parent to F1 hybrid offspring) graft treatment with immunotoxin led to a prolongation of recipient survival compared with groups receiving similar transplants without immunotoxin treatment. An additive effect on survival was observed when the host was treated with cyclosporin. The effect of immunotoxin was greater than that of mesenteric lymphadenectomy in increasing host survival. The effect of graft treatment with the immunotoxin on cellular migration from graft to host lymphoid tissues was assessed in fully allogeneic transplantation (PVG to DA). Host lymphoid tissues were subjected to immunohistochemical analysis using a MoAb specific for donor class I MHC antigens. Graft treatment with the immunotoxin led to a significant decrease in the number of graft cells found in host lymphoid tissues 7 days after transplantation. However, this effect was less marked than that achieved by graft mesenteric lymphadenectomy. With our current protocol graft treatment with a specific T cell immunotoxin can significantly reduce but not abolish GVH reactivity in rat small bowel transplantation.
Clark
C L
CL
Professional Surgical Unit, St Bartholomew's Hospital, West Smithfield, London, UK.
Smith
G J
GJ
Crane
P W
PW
Price
B A
BA
Lear
P A
PA
Fabre
J W
JW
Wood
R F
RF
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015703:Antigens, CD / Q000276:immunology; D018956:CD5 Antigens; D002465:Cell Movement / Q000187:drug effects; D016572:Cyclosporine / Q000627:therapeutic use; D006082:Graft Enhancement, Immunologic / Q000379:methods*; D006086:Graft vs Host Disease / Q000517:prevention & control*; D000922:Immunotoxins / Q000627:therapeutic use*; D007421:Intestine, Small / Q000637:transplantation*; D008197:Lymph Node Excision; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D011917:Rats, Inbred Lew; D011919:Rats, Inbred Strains; D012276:Ricin / Q000627:therapeutic use*; D013154:Spleen / Q000187:drug effects; D013601:T-Lymphocytes / Q000276:immunology*
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D018956:CD5 Antigens; D000922:Immunotoxins; D016572:Cyclosporine; D012276:Ricin